Ultrahuman and Abu Dhabi Build Biological Age Model for UAE Rollout
Ultrahuman and Abu Dhabi will validate a device agnostic biological age model for two years before phased rollout across UAE digital health platforms.
Summary
On October 12, 2026, Bengaluru based Ultrahuman signed a two-year memorandum of understanding with the Abu Dhabi Public Health Center to develop and clinically validate a biological age model for eventual UAE-wide access. It will combine clinical biomarkers with data from rings, wrist devices, straps and patches to estimate aging speed and assess sleep, activity, cardiovascular health and metabolism. A phased rollout through TAMM and Sahatna has no announced timetable.
CEO Mohit Kumar called the project Ultrahuman’s first national-scale health algorithm deployment, extending the company beyond hardware and its roughly 800,000 smart ring sales. The UAE, among its 10 largest markets after nearly five years, generates 4% to 5% of revenue and has 25% higher retention than other markets. Government deployment will also reach beyond Ultrahuman’s typical 25 to 43 year old users.
The model was developed from users’ chronological ages, wearable signals and, in some cases, blood tests. It will operate on UAE data without being trained on it, and Ultrahuman says it will receive no personally identifiable information. Oura separately partnered with the Department of Health Abu Dhabi in May to combine wearable and longitudinal health data, initially targeting women’s health and cardiometabolic risk. Kumar knows of no rival working on this specific age model and declined to characterize Oura’s scope. Ultrahuman is also developing a ring capable of running software, AI interactions and games on the device.
Positives
- Rings, wrist devices, straps and patches can all supply data, avoiding dependence on Ultrahuman hardware.
- TAMM and Sahatna will eventually give people across the UAE access to their estimated biological age.
- Ultrahuman will receive no personally identifiable information through the government program.
- The UAE delivers 25% higher retention than Ultrahuman’s other markets and contributes 4% to 5% of revenue.
- Government deployment will expose the model to broader age groups than Ultrahuman’s typical 25 to 43 year old customers.
Risks & concerns
- Two years of research and clinical validation remain before the model’s effectiveness is established.
- No timetable has been provided for the phased rollout through TAMM and Sahatna.
- The model was built from Ultrahuman’s existing users and will not be trained on UAE data.
- Ultrahuman’s current customer base is concentrated between ages 25 and 43, limiting its existing population coverage.
- Oura’s separate Abu Dhabi partnership intensifies competition in preventive health and wearable data services.